TY - JOUR
T1 - Innovations in the prevention and treatment of postpartum hemorrhage
T2 - Analysis of a novel medicines development pipeline database
AU - McDougall, Annie R.A.
AU - Goldstein, Maya
AU - Tuttle, Andrew
AU - Ammerdorffer, Anne
AU - Rushwan, Sara
AU - Hastie, Roxanne
AU - Gülmezoglu, A. Metin
AU - Vogel, Joshua P.
N1 - Funding Information:
The authors would like to thank the extended team at Policy Cures Research who assisted with the research and development of the AIM medicines database: Dr Alex Ankomah, Dr Nick Chapman, Thomas Clifton, Anna Doubell, Madeleine Kearney, Phi-Yen Nguyen, and Omotola Olufemi. The authors would also like to thank Dr Sarah A. Marshall and Dr Neville Fields (Ritchie Centre, Department of Obstetrics and Gynecology, Monash University) for assistance with external review of the database.
Funding Information:
AMG and AA are Concept Foundation staff who provide regulatory assistance to the developers of heat‐stable carbetocin and inhaled oxytocin. SR reports funding to Concept Foundation from MSD for Mothers. AA, AMcD, AMG, AT, JPV, and MG report grant funding to Concept Foundation from the Bill & Melinda Gates Foundation (Investment ID INV‐023749). Outside the present study, A. M. G. reports an honorarium from Ferring Pharmaceuticals paid to Concept Foundation for PPH panel participation (International Confederation of Midwives Conference, June 23, 2021). Other authors have no conflicts of interest to declare.
Publisher Copyright:
© 2022 The Authors. International Journal of Gynecology & Obstetrics published by John Wiley & Sons Ltd on behalf of International Federation of Gynecology and Obstetrics.
PY - 2022/6
Y1 - 2022/6
N2 - Background: A significant barrier to improving prevention and treatment of postpartum hemorrhage (PPH) is a lack of innovative medicines that meet the needs of women and providers, particularly those in low-and middle-income countries (LMICs). The Accelerating Innovation for Mothers (AIM) project established a new database of candidate medicines under development for five pregnancy-related conditions between 2000 and 2021. Objective: To systematically identify and rank candidates for prevention and treatment of PPH. Search Strategy: Adis Insight, Pharmaprojects, WHO ICTRP, PubMed, and grant databases were searched to develop the AIM database. Selection Criteria: AIM database was searched for candidates being evaluated for PPH prevention and treatment, regardless of phase. Data Collection and Analysis: Candidates were ranked as high, medium, or low potential based on prespecified criteria. Analysis was primarily descriptive, describing candidates and development potential. Main Results: Of the 444 unique candidates, only 39 pertained to PPH. One was high potential (heat-stable/inhaled oxytocin) and three were medium potential (melatonin, vasopressin and dofetilide via nanoparticle delivery). Conclusion: The pipeline for new PPH medicines is concerningly limited, lacking diversity, and showing little evidence of novel technologies. Without significant investment in early-phase research, it is unlikely that new products will emerge.
AB - Background: A significant barrier to improving prevention and treatment of postpartum hemorrhage (PPH) is a lack of innovative medicines that meet the needs of women and providers, particularly those in low-and middle-income countries (LMICs). The Accelerating Innovation for Mothers (AIM) project established a new database of candidate medicines under development for five pregnancy-related conditions between 2000 and 2021. Objective: To systematically identify and rank candidates for prevention and treatment of PPH. Search Strategy: Adis Insight, Pharmaprojects, WHO ICTRP, PubMed, and grant databases were searched to develop the AIM database. Selection Criteria: AIM database was searched for candidates being evaluated for PPH prevention and treatment, regardless of phase. Data Collection and Analysis: Candidates were ranked as high, medium, or low potential based on prespecified criteria. Analysis was primarily descriptive, describing candidates and development potential. Main Results: Of the 444 unique candidates, only 39 pertained to PPH. One was high potential (heat-stable/inhaled oxytocin) and three were medium potential (melatonin, vasopressin and dofetilide via nanoparticle delivery). Conclusion: The pipeline for new PPH medicines is concerningly limited, lacking diversity, and showing little evidence of novel technologies. Without significant investment in early-phase research, it is unlikely that new products will emerge.
KW - innovation
KW - medicines
KW - postpartum hemorrhage
KW - prevention
KW - treatment
UR - https://www.scopus.com/pages/publications/85132871058
U2 - 10.1002/ijgo.14200
DO - 10.1002/ijgo.14200
M3 - Article
C2 - 35762804
AN - SCOPUS:85132871058
SN - 0020-7292
VL - 158
SP - 31
EP - 39
JO - International Journal of Gynecology and Obstetrics
JF - International Journal of Gynecology and Obstetrics
IS - S1
ER -